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Abstract
An adequate intake of branched-chain amino acids (BCAA) is required for protein synthesis and metabolic functions, including insulin metabo-
lism. Emerging studies found positive associations between BCAA and the risk of various diseases sharing aetiological aspects with colorectal
cancer (CRC), including type 2 diabetes, obesity and pancreatic cancer. We investigated the relation between dietary BCAA and CRC using data
from amulticentric Italian case–control study, including 1953 cases of CRC (of these, 442 of sigmoid colon) and 4154 hospital controls with acute,
non-neoplastic diseases. A validated FFQ was used to estimate the participants’ usual diet and to assess dietary intakes of various nutrients,
including energy, BCAA and Ca. OR and corresponding CI were computed by multiple logistic regression models adjusted for age, sex and
other confounding factors, including total energy intake. BCAA intake was inversely related to CRC risk (OR for the highest v. the lowest quintile
0·73; 95 % CI 0·55, 0·97), but the association was attenuated after adjustment for Ca intake (OR 0·90; 95 % CI 0·65, 1·25). An inverse association
with sigmoid colon cancer risk also remained after adjustment for other dietary factors, including Ca intake (OR 0·49; 95 % CI 0·27, 0·87). This
study provides supporting evidence that higher levels of dietary BCAA intake are not associated with an increase of CRC risk, but confirms that
they may be related to a reduced risk of sigmoid colon cancer.
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Branched-chain amino acids (BCAA) are essential amino acids
(leucine, isoleucine and valine). Their main sources are meat,
fish, legumes, dairy products and eggs. An adequate intake of
BCAA is required for protein synthesis and several metabolic
and signalling functions, including insulin metabolism(1,2).
Several studies suggested positive associations between
dietary or plasma BCAA and the risk of various diseases,
including insulin resistance, type 2 diabetes, obesity, CVD
and pancreatic cancer(1,3,4), which may share aetiological
aspects and mechanisms with colorectal cancer (CRC).
There is evidence of an elevated risk of CRC with higher con-
sumption of red meat(5), the most major source of BCAA. A
study based on three US cohorts (The Nurses’ Health Study
I and II, the Health Professionals Follow-up Study) including
a total of 3309 incident cases investigated the association
between dietary BCAA and CRC risk, reporting no association
with the intake of leucine, isoleucine and valine(6). However, it
found inverse association for distal colon in the Health
Professionals Follow-up Study and rectum in The Nurses’
Health Study. A case–control Japanese study on 629 cases
of colorectal adenoma found that higher levels of plasma
BCAA were inversely associated with adenoma risk, a precur-
sor lesion of CRC, in men but not in women(7).
To provide information on the issue, this article investigates
the relation between dietary BCAA and CRC with specific focus
on distal subsites using data from a multicentric case–control
study of CRC(8).
Methods
A case–control study of CRC was conducted between January
1992 and June 1996 in six Italian areas(8). Cases were subjects
with incident, histologically confirmed CRC and no previous
diagnoses of cancer. They included 1953 subjects with cancer
of the colon-rectum (1125 men and 828 women, median age
Abbreviations: BCAA, branched-chain amino acid; CRC, colorectal cancer; ICD-9, International Classification of Diseases, 9th edition.
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62, range 19–79, years) according to the International
Classification of Diseases, 9th edition (ICD-9). Of these, 185were
grouped into the right colon, including the caecum, ascending
colon and hepatic flexure (ICD-9 153.0, 153.4, 153.5 and
153.6), 188 into the transverse and descending colon (ICD-9
153.1, 153.2 and 153.7), 442 into the sigmoid colon
(ICD-9 153.3) and 728 into the rectum, including the rectosig-
moid junction (ICD-9 154.0–154.1). The remaining 410 cases
belonged to other or unspecified anatomic subsites. One hun-
dred forty-four cases (7·4 %) had a family history of CRC in
first-degree relatives; 26 (1·3 %) received a previous diagnosis
of intestinal adenomas.
Controls were patients with no history of cancer admitted to
major teaching and general hospitals in the same catchment
areas of cases for acute, non-neoplastic conditions, unrelated
to hormonal or digestive tract diseases or to long-term modifica-
tions of diet. They included 2073 men and 2081 women aged
19–74 years (median age 58 years) from the following diagnostic
categories: traumas (27 %) and other orthopaedic disorders
(24 %), acute surgical conditions (18 %), eye diseases and other
miscellaneous diseases (31 %). Seventy-six controls (1·8 %) had a
family history of CRC in first-degree relatives; 39 (0·9 %) received
a diagnosis of intestinal adenomas. There was no difference in
terms of adenomas between cases and controls (P for χ2 test,
1·63). On average, about 4 % cases and controls, when invited,
refused to participate in the study.
A structured questionnaire was used to collect data on socio-
demographic characteristics, such as education and occupation,
lifetime smoking and alcohol-drinking habits, physical activity,
anthropometric measures, personal medical history and cancer
family history.
A reproducible(9) and valid(10) FFQ was used to assess usual
diet, including questions on the average weekly consumption of
seventy-eight foods, food groups or recipes, and of five alcoholic
beverages. From these data, we obtained the intakes of energy
and selected nutrients, including leucine, isoleucine, valine and
Ca, using an Italian food composition database, appropriately
integrated with other data when needed(8,11).
Given the high collinearity between the intakes of leucine,
isoleucine and valine (r ~ 1·00), we focused on the analyses
of total BCAA instead of single BCAA intakes. We categorised
BCAA intakes into quintiles (based on the distribution of con-
trols) and estimated the OR and the 95 % corresponding CI
through multiple logistic regression models. The core model
included terms for sex, age (quintiles; categorically), study centre
(categorically), education (<7, 7–11 and ≥12 years; categori-
cally), occupational physical activity (low, medium and high;
categorically), BMI (quintiles; categorically), alcohol consump-
tion (quartiles; categorically), tobacco smoking (never, former,
<15 and ≥15 cigarettes/d current smokers; categorically), family
history of CRC (yes/no), aspirin use (yes/no), menopausal status
and postmenopausal hormone use (premenopause, never and
ever users in postmenopause; in women only, categorically)
and total energy intake (quintiles; categorically).
BCAA intake was also entered as continuous variables for an
increment of the difference between the fourth and first quintile
upper cut points as a measure of variability in the data. Further
models also included one term for the intake of protein, fibre,
folate, vitamin D, Ca and various BCAA sources (red meat,
chicken and poultry, fish and dairy products) at a time (quintiles;
categorically).
Results
Table 1 gives themeans and standard deviations of BCAA intake,
age, BMI, and selected nutrient intakes and food consumptions
according to the BCAA quintiles among controls. The distribu-
tion of potential confounders was reported across BCAA quin-
tiles. Participants with higher BCAA intake were younger and
more frequently women. They were more frequently alcohol
drinkers and current smokers. Women with higher BCAA intake
were more likely to be in postmenopause. Participants with
higher BCAA intake reported a higher intakes of energy, pro-
teins, fibre, folate, vitamin D and Ca.
Table 2 shows the mean intake of total BCAA (16·1 g/d) and
their quintile upper cut points (12·1, 14·5, 16·7 and 19·8 g/d)
among controls. Multiple logistic regression OR of BCAA intake
and their corresponding 95 %CIwere given according to quintile
(with the first quintile as a reference category) as well as continu-
ous increment of intake, for all CRC and by anatomic subsites,
from two major confounder adjusted models which differ by
the addition of Ca intake.
We observed an inverse association between BCAA intake
and CRC risk (OR for the highest v. the lowest quintile 0·73;
95 % CI 0·55, 0·97; Pfor trend, 0·023) that however disappeared
after adjustment of Ca intake (OR 0·90; 95 % CI 0·65, 1·25; Pfor
trend, 0·49). The continuous OR was 0·82 (95 % CI 0·69, 0·98)
in the first and 0·94 (95 % CI 0·77, 1·14) in the second model.
Analysing separately anatomic subsites, we observed a linear
inverse association for sigmoid colon (OR for the highest v.
the lowest quintile 0·42; 95 %CI 0·25, 0·72; Pfor trend, 0·001) which
remained after the adjustment for Ca (OR 0·49; 95 %CI 0·27, 0·87;
Pfor trend, 0·013), with continuous OR about 0·60 in both models.
No association was found for other subsites.
Table 3 gives the mean intake of leucine (7·3 g/d), isoleucine
(4·1 g/d) and valine (4·7 g/d), as well as the logistic regression
OR for their quintile and for a continuous increment of intake
overall according to the two adjusted models. The OR for the
three single BCAA intakes were almost identical to the OR for
total BCAA.
The estimates did not appreciably differ when considering
further adjustment for selected measures of dietary quality and
BCAA sources (Table 4).
Discussion
In this large case–control study, we found an inverse association
between dietary BCAA (leucine, isoleucine and valine) and CRC
risk inmultivariablemodels, which, however, was not confirmed
after adjustment for Ca intake. When separately analysing CRC
sites, we observed that BCAA intake was inversely associated
with sigmoid colon cancer risk also after adjustment for other
dietary factors, including Ca intake.
Our data reinforce previous results from three large USA
cohorts (the Nurses’ Health Study I and II, and the Health
Professionals Follow-up Study) that did not support the
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hypothesis of a positive association between dietary BCAA and
CRC risk(6), but suggested an inverse association for distal colon
cancer, also after adjustment of Ca intake, as well as for rectal
cancer(6). In the Nurses’ Health Study and Health Professionals
Follow-up Study cohorts, similar differential associations for dis-
tal cancer as compared with other colorectal subsites were
observed for processed and unprocessed meat intake, too(12).
The absence of a clear mechanistic or biological explanation
for different effects of BCAA on CRC risk by location leaves how-
ever the interpretation open to further investigations and discus-
sion. The BCAA metabolism and BCAT1 activity (enzyme
involved in the first step of BCAA catabolism) could play func-
tional roles in the progression of tumours(4). Increased levels
of plasma BCAA were associated with an increased risk of pan-
creatic cancer in a nested case–control study of a Japan cohort(3).
They were also positively related to obesity, diabetes and insulin
resistance(13–15), which are known risk factors for CRC(16,17).
BCAA up-regulate glucose transporters and activate insulin
secretion(2). High BCAA levels activate the mammalian target
of rapamycin complex 1 that could be linked to insulin
resistance(1) and elevated levels of blood insulin could cause
alteration in the insulin-like growth factor, which is involved
in the development of CRC(18).
BCAA supplementation in mice with obesity and hyperinsu-
linaemia was found to improve insulin resistance and to inhibit
the activation of the insulin-like growth factor/insulin-like
growth factor-I receptor axis, thereby preventing the develop-
ment of colonic premalignancies in an obesity-related colon
cancer model(19). However, only a few studies, on circulating
BCAA levels tend to support the hypothesis of an inverse asso-
ciation between BCAA and CRC risk, with unconvincing results.
In particular, a metabolomics study found a significant reduction
in terms of leucine and valine serum concentrations intake in
sixty-four CRC cases as compared with sixty-five controls. This
difference, however, was not confirmed when another MS
instrument was used(20). Moreover, a case–control study from
Japan reported that plasma BCAA concentration was inversely
associated with the risk of colorectal adenoma in 629 cases
and 584 controls(7). However, besides the difference in the out-
come and the limitations due to a cross-sectional design, there is
low agreement between dietary and plasma BCAA levels(21)
which may explain the difference with null results, observed
in our and previous findings on dietary BCAA. Plasma BCAA
can be interpreted as a marker of a metabolism alteration of
BCAA levels related to insulin resistance(22).
Major sources of BCAA intake in our data were red meat
(26 %), dairy products (13 %), poultry (12 %) and fish (7 %).
Most models further adjusted for these food groups are clearly
overadjusted, but did not alter the results, as did the inclusion
of other nutrients in the models. In particular, no appreciable
Table 1. Distribution of potential confounders by quintiles of branched-chain amino acid (BCAA) intake among 4154 controls, Italy, 1992–1996
(Mean values and standard deviations; percentages)
Quintiles of BCAA intake
P *
I II III IV V
Mean SD Mean SD Mean SD Mean SD Mean SD
BCAA intake (g/d)
Total BCAA 10·2 1·6 13·3 0·7 15·5 0·6 18·1 0·9 23·5 4·1 <0·001
Leucine (g/d) 4·6 0·7 6·1 0·3 7·1 0·3 8·2 0·4 10·7 1·9 <0·001
Isoleucine (g/d) 2·6 0·4 3·3 0·2 4·0 0·2 4·6 0·2 6·0 1·0 <0·001
Valine (g/d) 3·0 0·5 3·9 0·2 4·6 0·2 5·3 0·3 6·9 1·2 <0·001
Women (%) 67·4 52·4 53·4 43·2 34·1 <0·001
Age (years) 58·0 11·0 57·4 10·5 56·0 11·2 55·5 11·4 54·6 11·7 <0·001
BMI (kg/m2) 25·7 4·3 25·7 4·0 26·0 3·9 25·8 3·8 26·0 3·8 0·53
Alcohol drinkers (%) 58·8 70·6 73·9 77·4 78·1 <0·001
Current smokers (%) 28·8 30·1 26·1 29·4 32·8 0·056
Family history of colorectal cancer (%) 1·4 2·5 1·7 1·2 2·3 0·21
Regular aspirin use 1·8 1·7 1·7 1·3 1·3 0·90
Medium/heavy occupational physical activity (%) 64·6 66·6 67·0 67·9 71·2 0·066
Postmenopausal among women (%) 73·8 68·7 66·0 64·4 69·6 0·022
Current hormone replacement therapy among
postmenopausal women (%)
8·7 9·0 13·0 7·8 9·1 0·26
Total energy intake (kcal/d)† 1575·7 414·6 2040·2 417·1 2340·2 427·1 2714·8 480·7 3464·9 821·5 <0·001
Total protein (g/d) 59·3 9·0 76·9 4·4 89·4 4·2 103·8 5·7 113·6 23·2 <0·001
Animal protein (g/d) 37·0 7·9 48·7 5·8 57·5 6·3 67·2 7·0 89·3 18·9 <0·001
Plant protein (g/d) 22·3 6·8 28·1 6·6 31·9 7·1 36·5 8·2 44·3 11·6 <0·001
Dietary fibre (g/d) 17·6 6·2 21·5 6·1 23·8 6·2 26·5 6·5 31·8 8·6 <0·001
Folate (μg/d) 189·5 54·9 235·4 54·7 262·4 57·3 291·6 56·5 361·2 83·9 <0·001
Vitamin D (IU/d) 2·1 1·0 2·7 1·1 3·2 1·2 3·6 1·2 4·5 1·6 <0·001
Ca (mg/d) 655·4 221·5 856·3 231·7 977·8 255·2 1147·5 307·1 1511·9 569·1 <0·001
Unprocessed red meat (servings/d) 2·7 1·6 3·6 1·7 4·3 1·8 4·9 2·0 6·2 2·6 <0·001
Processed red meat (servings/d) 2·1 1·6 2·4 1·7 2·8 1·9 3·1 2·1 3·8 2·8 <0·001
Chicken and poultry (servings/d) 1·4 1·1 1·6 1·2 1·8 1·2 2·0 1·2 2·5 1·6 <0·001
Fish (servings/d) 1·4 1·0 1·6 1·2 1·9 1·2 2·0 1·1 2·3 1·4 <0·001
Dairy products (servings/d) 3·1 1·8 4·0 2·0 4·3 2·0 4·9 2·3 6·2 4·1 <0·001
* For continuous variables: one-way ANOVA; for categorical variables: χ21 test.
† To convert kcal to kJ, multiply by 4·184.
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Table 2. Multiple logistic regression-derived OR and corresponding 95% CI according to quintile of branched-chain amino acid (BCAA) intake among 1953 cases with colorectal cancer and 4154 controls overall and by
anatomic subsites, Italy, 1992–1996
(Mean values and standard deviations; odds ratios and 95% confidence intervals)
BCAA Mean SD*





1‡ 2 3 4 5
OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Lower/upper cut points (g/d) 16·13 4·96 3·91/12·10 12·10/14·48 14·48/16·70 16·71/19·82 19·83/60·45
Controls 831 831 831 831 830
Colon-rectum
Cases 391 396 367 393 406
Model I|| 1 0·89 0·73, 1·09 0·76 0·61, 0·96 0·76 0·59, 0·98 0·73 0·55, 0·97 5·20 0·023 0·82 0·69, 0·98
Model II¶ 1 0·96 0·78, 1·18 0·86 0·67, 1·10 0·90 0·68, 1·19 0·90 0·65, 1·25 0·47 0·49 0·94 0·77, 1·14
Right colon
Cases 33 34 36 49 33
Model I|| 1 0·75 0·43, 1·31 0·71 0·38, 1·30 0·86 0·45, 1·66 0·52 0·24, 1·12 1·43 0·23 0·63 0·40, 1·00
Model II¶ 1 0·82 0·46, 1·45 0·83 0·43, 1·58 1·13 0·55, 2·34 0·76 0·32, 1·82 0·01 0·91 0·75 0·44, 1·27
Transverse and descending colon
Cases 31 38 35 49 35
Model I|| 1 1·07 0·61, 1·87 0·93 0·50, 1·75 1·10 0·56, 2·17 0·80 0·37, 1·74 0·23 0·63 0·92 0·57, 1·48
Model II¶ 1 1·32 0·73, 2·37 1·24 0·63, 2·44 1·61 0·76, 3·43 1·22 0·50, 2·95 0·25 0·62 1·07 0·63, 1·83
Sigmoid colon
Cases 95 90 100 82 75
Model I|| 1 0·80 0·56, 1·13 0·75 0·51, 1·12 0·53 0·34, 0·84 0·42 0·25, 0·71 11·64 0·001 0·58 0·41, 0·80
Model II¶ 1 0·85 0·59, 1·23 0·83 0·54, 1·27 0·60 0·36, 0·99 0·49 0·27, 0·87 6·14 0·013 0·61 0·42, 0·89
Rectum
Cases 33 27 30 37 32
Model I|| 1 1·00 0·75, 1·33 0·85 0·61, 1·18 0·91 0·63, 1·32 0·93 0·61, 1·40 0·24 0·62 0·86 0·66, 1·10
Model II¶ 1 1·05 0·78, 1·42 0·93 0·65, 1·33 1·06 0·71, 1·59 1·16 0·72, 1·85 0·23 0·63 0·98 0·74, 1·31
* Mean intake and standard deviation among controls.
† Control generated quintiles.
‡ Reference category.
§ Estimated for an increment equal to the difference between the fourth and the first cut-off quintile.
|| Adjusted for sex, age, study centre, education, occupational physical activity, BMI, alcohol consumption, tobacco smoking, family history of colorectal cancer, aspirin use, menopausal status and postmenopausal hormone use, and total energy intake.
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effect modification was observed in the model including dairy
products, whose consumption is partially correlated with Ca
intake. Only the adjustment for fish consumption and vitamin
D slightly increased the OR estimates (0·82 and 0·87 for the high-
est v. the lowest quintile of BCAA intake, respectively), sug-
gesting a possible role of vitamin D, in addition to Ca, in
explaining the observed associations with CRC, in line with
the literature(23–26). In an additional model, including both
dietary Ca and vitaminD, no associationwith BCAAwas evident.
This study was sufficiently large to obtain precise risk esti-
mates for BCAA intake. Cases and controls came from compa-
rable catchment areas, participation was virtually complete
reducing potential selection bias. Moreover, the hospital setting
is unlikely to have reduced the comparability of diet recall by
cases and controls(27), and the estimate of BCAA intake derives
from a satisfactorily reproducible and valid FFQ(9,10). A limitation
of this study is the lack of plasma samples to assess the circulating
BCAA levels and to compare variability and risk estimates with
results fromdietary BCAA.With reference to confounding, all OR
were adjusted for age and other major confounding factors,
including education, physical activity and total energy.
In conclusion, this study provides supporting evidence that
higher levels of dietary BCAA intake are not associated with
an increase of CRC risk, but may be related to a reduced risk
of sigmoid colon cancer.
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Table 3. Multiple logistic regression-derived OR and corresponding 95%CI according to quintile of leucine, isoleucine and valine intakes among 1953 cases
with colorectal cancer and 4154, Italy, 1992–1996
(Mean values and standard deviations; odds ratios and 95% confidence intervals)
Mean SD*





1‡ 2 3 4 5
OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Leucine 7·34 1·45
Model I|| 1 0·91 0·75, 1·11 0·75 0·60, 0·94 0·78 0·60, 1·00 0·73 0·55, 0·97 5·32 0·021 0·83 0·70, 0·98
Model II¶ 1 0·98 0·80, 1·21 0·85 0·66, 1·08 0·92 0·70, 1·22 0·91 0·65, 1·22 0·46 0·50 0·95 0·78, 1·15
Isoleucine 4·06 1·25
Model I|| 1 0·84 0·69, 1·03 0·76 0·61, 0·96 0·73 0·57, 0·94 0·71 0·53, 0·94 5·66 0·017 0·82 0·69, 0·98
Model II¶ 1 0·90 0·73, 1·10 0·85 0·67, 1·08 0·85 0·64, 1·12 0·86 0·63, 1·18 0·84 0·36 0·93 0·77, 1·12
Valine 4·73 1·45
Model I|| 1 0·86 0·71, 1·05 0·73 0·58, 0·91 0·75 0·58, 0·96 0·71 0·53, 0·94 5·65 0·018 0·82 0·69, 0·97
Model II¶ 1 0·92 0·75, 1·13 0·82 0·64, 1·04 0·88 0·67, 1·17 0·88 0·63, 1·22 0·59 0·44 0·93 0·77, 1·13
* Mean intake and standard deviation among controls.
† Control generated quintiles.
‡ Reference category.
§ Estimated for an increment equal to the difference between the fourth and the first cut-off quintile.
|| Adjusted for sex, age, study centre, education, occupational physical activity, BMI, alcohol consumption, tobacco smoking, family history of colorectal cancer, aspirin use, meno-
pausal status and postmenopausal hormone use, and total energy intake.
¶ Further adjusted for Ca intake.
Table 4. Multiple logistic regression-derived OR and corresponding 95% CI according to quintile of branched-chain amino acid (BCAA) intake among 1953
cases with colorectal cancer and 4154 controls after adjustment of dietary factors, Italy, 1992–1996
(Odds ratios and 95% confidence intervals)





1† 2 3 4 5
OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Model I§ þ protein 1 0·68 0·46, 1·01 0·63 0·37, 1·07 0·47 0·25, 0·90 0·41 0·20, 0·87 4·02 0·045 0·83 0·65, 1·05
Model I§ þ fibre 1 0·91 0·75, 1·10 0·79 0·63, 0·99 0·78 0·61, 1·01 0·76 0·57, 1·01 5·20 0·023 0·82 0·69, 0·98
Model I§ þ folate 1 0·91 0·74, 1·11 0·80 0·63, 1·00 0·81 0·62, 1·05 0·73 0·55, 0·97 2·73 0·098 0·86 0·72, 1·03
Model I§ þ vitamin D 1 0·93 0·76, 1·14 0·83 0·65, 1·05 0·85 0·65, 1·12 0·87 0·64, 1·19 0·85 0·36 0·93 0·77, 1·12
Model I§ þ red meat 1 0·87 0·71, 1·07 0·74 0·58, 0·93 0·72 0·56, 0·94 0·69 0·51, 0·92 6·63 0·010 0·79 0·66, 0·95
Model I§ þ fish 1 0·92 0·75, 1·12 0·81 0·64, 1·01 0·82 0·63, 1·06 0·82 0·13, 1·09 2·11 0·15 0·88 0·74, 1·05
Model I§ þ chicken and
poultry
1 0·89 0·73, 1·08 0·75 0·60, 0·95 0·765 0·58, 0·97 0·72 0·54, 0·97 5·02 0·025 0·82 0·68, 0·98
Model I§ þ dairy products 1 0·89 0·73, 1·09 0·77 0·61, 0·97 0·77 0·60, 1·00 0·75 0·56, 1·00 4·08 0·043 0·84 0·70, 1·00
* Control generated quintiles.
† Reference category.
‡ Estimated for an increment equal to the difference between the fourth and the first cut-off quintile.
§ Adjusted for sex, age, study centre, education, occupational physical activity, BMI, alcohol consumption, tobacco smoking, family history of colorectal cancer, aspirin use, meno-
pausal status and postmenopausal hormone use, and total energy intake.
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